IMRNW (Immuron) OCF Margin %: -61.01% (As of Dec. 2025)


What is Immuron OCF Margin %?

Immuron IMRNW OCF Margin % is -61.01% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 956 Biotechnology companies, Immuron ranks better than 50.73% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Immuron's Cash Flow from Operations for the six months ended in Dec. 2025 was $-1.70 Mil. Immuron's Revenue for the six months ended in Dec. 2025 was $2.78 Mil. Therefore, Immuron's OCF Margin % for the quarter that ended in Dec. 2025 was -61.01%.

As of today, Immuron's current OCF Yield % is -44.09%.

The historical rank and industry rank for Immuron's OCF Margin % or its related term are showing as below:


During the past 11 years, the highest OCF Margin % of Immuron was -75.37%. The lowest was -2793.84%. And the median was -166.98%.

IMRNW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Immuron OCF Margin % Related Terms

Immuron OCF Margin % Historical Data

* Premium members only.

The historical data trend for Immuron's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron OCF Margin % Chart

Immuron Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,784.82 -411.15 -143.85 -119.90 -84.21

Immuron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.03 -152.22 -100.00 -65.11 -61.01

Immuron OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Immuron's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.995/4.744
=-84.21 %

Immuron's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.696/2.78
=-61.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -61.01% mean?
Immuron (IMRNW) has a OCF Margin % of -61.01% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immuron and its competitors. According to the industry distribution chart, Immuron ranks #471 out of 956 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Immuron's OCF Margin % too high?
Immuron's current OCF Margin % is -61.01%. Based on the distribution chart, Immuron ranks #471 out of 956 companies in the Biotechnology industry, which is above the industry midpoint.
How does Immuron's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #471 out of 956 companies for OCF Margin %. This puts Immuron in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immuron and its competitors. Immuron's current OCF Margin % is -61.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (IMRNW) has a current OCF Margin % of -61.01%. The current OCF Margin % is -61.01%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Immuron (IMRNW), the current OCF Margin % is -61.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immuron Business Description

Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.